Discover
NVNO
enVVeno Medical Corporation
10.83
2 x 7.82
2 x 13.82
bid
ask
+
0.12
1.12%
2 @ 04:00 PM
11.09 +0.26 (2.40%)
| Ytd | -3.56% | |
| 1y | -92.23% |
10.70
day range
10.90
8.67
52 week range
196.70
| Open | 10.70 | Prev Close | 10.71 | Low | 10.70 | High | 10.90 | Mkt Cap | 7.23M |
| Vol | 4.25K | Avg Vol | 10.19K | EPS | -31.20 | P/E | N/A | Forward P/E | -2.45 |
| Beta | 1.22 | Short Ratio | 4.12 | Inst. Own | 29.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 10.71 | 200-d Avg | 14.91 | 1yr Est | 18.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-30 | 2024-09 | 0 | -0.35 | N/A | N/A |
| 2024-07-31 | 2024-06 | 0 | -0.31 | N/A | N/A |
| 2024-07-31 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | 0 | -0.31 | N/A | N/A |
| 2024-05-08 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-02-29 | 2023-12 | 0 | -0.32 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-12 | ALAVI HAMED | Chief Technology Officer | 0.00 | Sale |
| 2024-12-18 | BERMAN ROBERT ANDREW | Chief Executive Officer | 222.24K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Kingdon Capital Management LLC | 859.26K | 2.50M | 4.90% |
| 2024-09-29 | Perceptive Advisors Llc | 694.32K | 2.02M | 3.96% |
| 2024-09-29 | Nantahala Capital Management, LLC | 596.92K | 1.74M | 3.40% |
| 2024-09-29 | Vanguard Group Inc | 589.14K | 1.71M | 3.36% |
| 2024-09-29 | Alyeska Investment Group, L.p. | 425.00K | 1.24M | 2.42% |
| 2024-09-29 | Adar1 Capital Management, LLC | 348.26K | 1.01M | 1.99% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 418.54K | 1.22M | 2.39% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 156.17K | 454.46K | 0.89% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 75.50K | 219.71K | 0.43% |
| 2024-10-30 | Fidelity Total Market Index Fund | 23.98K | 69.79K | 0.14% |
| 2024-10-30 | iShares Micro Cap ETF | 23.88K | 69.49K | 0.14% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 20.49K | 59.62K | 0.12% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2026-01-20 |
| 1 : 25 | 2020-11-30 |